Hims & Hers Health (NYSE:HIMS) Insider Sells $100,576.66 in Stock

October 16, 2026 by InsiderTrades.com

Key Points

Insider sale: Soleil Boughton sold 3,461 Hims & Hers shares for approximately $100,577 under a pre-arranged Rule 10b5-1 plan, reducing her position by 1.15% while retaining 297,348 shares.
Operating performance: Quarterly revenue rose 38.2% year over year to $753.2 million, exceeding estimates, but the company reported an adjusted loss of $0.37 per share versus the expected $0.05 loss.
Key risks and outlook: The stock faces legal and regulatory pressure, including a securities-fraud class-action lawsuit, while analysts maintain a consensus “Hold” rating with an average price target of $32.43.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,461 shares of the business's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total transaction of $100,576.66. Following the transaction, the insider owned 297,348 shares in the company, valued at $8,640,932.88. This represents a 1.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks

Soleil Boughton also recently made the following trade(s):

On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.17, for a total transaction of $100,957.37.
On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96.
On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Trading Up 6.5%

HIMS opened at $29.53 on Friday. The stock has a market cap of $6.89 billion, a PE ratio of -46.88 and a beta of 2.44. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The business has a 50 day moving average of $29.32 and a 200-day moving average of $28.74. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $63.63.

Is the Market Right or Wrong About These 4 High Short Interest Stocks?

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company's revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.17 earnings per share. Equities research analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after buying an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System lifted its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock worth $48,549,000 after buying an additional 280,900 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $46,220,000. Bienville Capital Management LLC bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $27,242,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Hims & Hers Health by 97.3% in the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock worth $26,620,000 after buying an additional 632,282 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health News Roundup

MarketBeat Week in Review – 08/24 - 08/28

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Australian expansion provides a growth catalyst. Hims & Hers launched its “Hers” women’s-health platform in Australia following its acquisition of Eucalyptus, expanding its offerings into weight management, hormonal health and hair regrowth. The move may support international revenue growth and broaden the company’s addressable market. Hims & Hers Expands Australian Women's Health Platform With Hers
Positive Sentiment: The stock’s rebound may reflect dip-buying. HIMS had suffered a sharp decline in the prior session amid regulatory and litigation concerns, potentially creating room for a technical rebound as investors reassessed the selloff.
Neutral Sentiment: Insider selling was limited and pre-arranged. Director Soleil Boughton sold 3,461 shares for approximately $100,577 under a Rule 10b5-1 trading plan, reducing her position by 1.15%. Because the transaction was scheduled in advance and represents a small portion of her holdings, it offers limited insight into current management sentiment. Soleil Boughton insider transaction
Negative Sentiment: Multiple law firms publicized a securities-fraud class action. The lawsuit follows the FTC’s federal complaint alleging serious business misconduct, including disputed privacy and billing practices. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead-plaintiff status. The litigation could raise legal costs, increase reputational pressure and create potential financial liabilities. The numerous October 14–15 announcements largely repeat the same case and should not be interpreted as separate lawsuits. Hims & Hers securities fraud class action notice

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 11th. Truist Financial raised their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a research report on Monday, August 24th. Citigroup lowered their price objective on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Barclays dropped their target price on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a report on Friday, August 21st. Finally, Zacks Research raised Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $32.43.

Read Our Latest Report on Hims & Hers Health

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.